Last reviewed · How we verify
ChimeriVax-WN02 vaccine — Competitive Intelligence Brief
phase 2
Infectious Diseases
Biologic
Live · refreshed every 30 min
Target snapshot
ChimeriVax-WN02 vaccine (ChimeriVax-WN02 vaccine) — Sanofi Pasteur, a Sanofi Company. ChimeriVax-WN02 vaccine works by inducing an immune response against the West Nile virus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ChimeriVax-WN02 vaccine TARGET | ChimeriVax-WN02 vaccine | Sanofi Pasteur, a Sanofi Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ChimeriVax-WN02 vaccine CI watch — RSS
- ChimeriVax-WN02 vaccine CI watch — Atom
- ChimeriVax-WN02 vaccine CI watch — JSON
- ChimeriVax-WN02 vaccine alone — RSS
Cite this brief
Drug Landscape (2026). ChimeriVax-WN02 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/chimerivax-wn02-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab